Kristen M Marks
Affiliation: Cornell University
- The first wave: HCV NS3 protease inhibitors telaprevir and boceprevirKristen M Marks
Division of Infectious Diseases, Weill Cornell Medical College, New York, NY, USA
Antivir Ther 17:1119-31. 2012..This review describes the clinical data supporting the approval and use of telaprevir and boceprevir, the algorithm for the use of these drugs, their adverse effects, as well as their important drug-drug interactions...
- Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapyKristen M Marks
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA
J Acquir Immune Defic Syndr 52:595-9. 2009..Before potent antiretroviral therapy, thrombocytopenia was observed frequently. Little is known about risk factors for or severity and consequences of thrombocytopenia since establishment of highly effective therapy for HIV...
- Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239Kristen M Marks
Division of Infectious Diseases, Weill Cornell Medical College, New York, NY Harvard School of Public Health, Boston, MA Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD Division of Infectious Diseases, University of California San Francisco Medical School, San Francisco, CA Medical Service, Department of Veterans Affairs, San Francisco, CA and HIV AIDS Division, San Francisco General Hospital, University of California, San Francisco, CA
J Acquir Immune Defic Syndr 65:345-9. 2014..29, lower limit of the exact 1-sided 90% confidence interval 5.9%). Over the 24 weeks of PIO monotherapy, alanine aminotransferase and aspartate aminotransferase declined significantly and correlated with improved metabolic parameters. ..
- Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infectionDaniel S Fierer
Divisions of Infectious Diseases, Mount Sinai School of Medicine, New York, NY, USA
Clin Infect Dis 56:1038-43. 2013....
- Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virusKristen M Marks
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA
J Infect Dis 192:1943-9. 2005..The prevalence and significance of steatosis in patients coinfected with human immunodeficiency virus (HIV) and HCV are not well characterized...
- Identification of substance use and dependence among patients with viral hepatitisColin B Jackson
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY 10065, USA
Dig Liver Dis 42:650-6. 2010..As drug abuse and addiction have been shown to decrease adherence to treatment of hepatitis C virus (HCV) or HIV, screening for substance use should be standard clinical practice in those undergoing an evaluation for these diseases...